A clinical trial (NCT00537368) using human CCL2 neutralizing monoclonal antibody CNTO888 could not completely inhibit CCL2 in prostate cancer patients and did not show clinical response compared to standard therapy. Here, CCL2 is linked to prostate carcinoma.